PMID: 9434284Jan 22, 1998Paper

Pharmacokinetic and pharmacological profiles of free and liposomal recombinant human erythropoietin after intravenous and subcutaneous administrations in rats

Pharmaceutical Research
H MoriyaT Nagai

Abstract

Recombinant human erythropoietin (Epo) is used frequently through intravenous (i.v.) and subcutaneous (s.c.) administration for the clinical treatment of the last stage of renal anemia. We encapsulated Epo in liposomes to develop an alternative administration route. The purpose of our study was to evaluate the pharmacokinetics and the pharmacological effects of liposomal Epo in comparison with the Epo after i.v. and s.c. administration to rats. Epo was encapsulated in liposomes composed of dipalmitoylphosphatidylcholine (DPPC) and soybean-derived sterol mixture (SS) prepared by the reversed-phase evaporation vesicle method. After filtration through a 0.1 micron polycarbonate membrane, liposomes were gel filtered (Epo/liposomes). Epo/liposomes showed higher pharmacological activity than Epo/liposomes before gel filtration after i.v. administration to rats. Non-encapsulated Epo lost its activity, whereas encapsulated Epo in liposomes retained it. The pharmacological effects of Epo/liposomes were greater than those of Epo after i.v. administration. Epo/liposomes afforded 3-9 times higher AUC, lower clearance and lower steady-state volume of distribution than Epo after both i.v. and s.c. administrations. Epo/liposomes had an improv...Continue Reading

Citations

Dec 8, 2004·The Journal of Pharmacology and Experimental Therapeutics·Danielle N McLennanSusan A Charman
Mar 27, 2003·Sports Medicine·Aurelie GaudardMichel Audran
Dec 2, 2008·Expert Opinion on Drug Delivery·Zhi-Yang ChangMing-Kung Yeh
Jun 20, 2007·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Sukyung Woo, William J Jusko
Jun 16, 2009·Journal of Liposome Research·Stefanie StrobachKarola Vorauer-Uhl

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.